Table 2.

Discontinuation of Study Drugs According to the Randomized Groups

	Aspirin (n = 502)	Clopidogrel (n = 499)	P*
Discontinuation† of study drug	32	63	0.001
Change to dual-antiplatelet treatment‡	23	23	0.98
Change to warfarin	5	10	0.19
Dyspepsia, peptic ulcer	3	5	0.47
Diarrhea	0	4	0.04
Rash	0	5	0.03
Other	1	16¶	<0.001

Values are given as numbers of patients.

^*P for differences between groups.

^†Discontinuation defined as being off the randomized principle for >28 days.

^‡Patients undergoing new percutaneous coronary intervention with stent implantation without reaching an end point.

^¶Includes dizziness (n=3), general discomfort (n=3), and discontinuation due to change of medication beyond the study protocol.